ArticleChemMedChem2026
Encapsulin-Protected Immunotherapeutic Complexes: Bacteria-Derived Nanoparticles for mRNA Delivery to Eukaryotic Cells.
Article in ChemMedChem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Encapsulins are protein nanocompartments that self-assemble into icosahedral structures that capture cargo proteins through a cargo-loading peptide (CLP). Here, we aimed to develop an mRNA delivery vector for eukaryotic cells by fusing the CLP from Myxococcus xanthus encapsulin cargoes with a short peptide that binds to a complementary RNA aptamer, creating an encapsulin-RNA adaptor peptide (ERAP). Additionally, we designed a chimeric mRNA (CmRNA) molecule for translation in eukaryotic cells, featuring an internal ribosome entry site (IRES) in the 5'-UTR to enable cap-independent translation. Downstream of the IRES, genes coding for model proteins were included. Finally, an aptamer that binds the Rev-derived peptide was added to the 3'-UTR of the RNA molecule. The CmRNA, ERAP, and encapsulin were coexpressed in Escherichia coli, and it was demonstrated that the produced nanocompartments contained the ERAP and bacterial RNA. The RNA was reverse-transcribed and identified by nested PCR, confirming that the encapsulin captured the CmRNA. qPCR analysis of encapsulin-protected immunotherapeutic complexes (EPICs) demonstrated the loading of 2.9 CmRNA molecules per particle. These RNA-loaded encapsulins were taken up by macrophage cells, and the expression of model proteins was confirmed. Finally, immunization of mice with these particles induced IgG antibodies against the model proteins.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.